Spironolactone Tablet, Film Coated
Product Images NDC 51655-636

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 51655-636). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 636 26)

Label for Spironolactone Tablets, USP 25 mg, containing 90 film-coated tablets. The label states Rx Only and includes storage instructions to keep at 20°-25°C, store in original container, and protect from light. It is labeled by Northwind Health Company, LLC, showing NDC 51655-636-26 and includes lot, expiration, and serialization information.*

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 01)

Chemical structure of spironolactone, showing its steroid core with attached functional groups including a lactone ring and a thioacetyl substituent.*

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 02)

A Kaplan-Meier survival curve graph displaying probability over months (0 to 48). Two lines represent groups treated with spironolactone (n=822) and placebo (n=841). The graph shows higher probability for the spironolactone group compared to placebo, with a log-rank p-value < 0.001 indicating statistical significance.*

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 03)

A forest plot displaying hazard ratios (HR) and 95% confidence intervals (CI) for various subgroups in a study comparing spironolactone versus placebo. Subgroups include age, sex, race, left ventricular ejection fraction (LVEF), heart failure type, NYHA class, diabetes presence, serum creatinine, creatinine clearance, potassium levels, and concurrent use of digoxin, ACE inhibitors, and beta blockers. The horizontal axis ranges from 0.2 to 1.4, indicating relative effectiveness, with spironolactone favored on the left and placebo on the right.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.